July 23, 2019 07:00 AM EDT

Frequency follows Astellas pact with $62M round to bankroll PhII of lead regenerative drug

Amber Tong

A few days ago Frequency Therapeutics got some high profile endorsement on its small molecule strategy for regenerative medicine, when Astellas offered $80 million upfront …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Frequency follows Astellas pact with $62M round to bankroll PhII of lead regenerative drug

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

FDA OKs the first-ever self-administered vaccine, for flu

The drug lobby's lawsuit against the IRA finds a sign of life after appeals court ruling

Biotech VC firm outlines plans for $100M fund

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Breaking down silos with a new quantitative approach to drug development

Fre­quen­cy fol­lows Astel­las pact with $62M round to bankroll PhII of lead re­gen­er­a­tive drug

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Frequency follows Astellas pact with $62M round to bankroll PhII of lead regenerative drug